Lund, Sweden, May 13, 2024 — Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it w ...

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and inves ...

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and inves ...

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), would like to invite inte ...

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) informs about its scheduled company presentations for March and April 2020.

Lund, Sweden, 9 October 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), holds today, on October 9, 2019, a Capital Markets Day for analysts, investors and media. The program i ...

Lund, 20 August 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will host a Capital Markets Day in Stockholm on 9 October, 2019, for investors, ...

Lund, Sweden, 18 January 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX:NEVPF) informs on its scheduled company presentation for January 2019.

Lund, Sweden, 20 April 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that its mitochondrial myopathy project, NVP025, has been selected for an oral presentati ...